The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation [PDF]
, 2017 core +1 more source
Does age matter? Optimizing AML treatment in older adults. [PDF]
Blood AdvLai C, Lin TL.
europepmc +1 more source
The management of advanced hepatocellular carcinoma: are we making progress in the era of targeted therapy? [PDF]
, 2011 Yau, TCC
core +6 more sources
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]
, 2018 Abboud, Camille N.
core +1 more source
Molecularly targeted therapy and immunotherapy in leukemias. [PDF]
J Hematol OncolCousin E +8 more
europepmc +1 more source
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches. [PDF]
Front OncolDeshpande S +6 more
europepmc +1 more source
Medulloblastoma response to mevalonate pathway inhibition is independent of p53 status. [PDF]
Biol DirectComer C +8 more
europepmc +1 more source
Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. [PDF]
Blood AdvBaeten JT +13 more
europepmc +1 more source
XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]
Cell Commun SignalXu TT +8 more
europepmc +1 more source
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. [PDF]
Am J HematolKonopleva M +8 more
europepmc +1 more source